Application of bzp in treatment of ischemic cardiovascular and cerebral vascular diseases
AssigneeZhejiang Ausun Pharmaceutical Co., Ltd.
InventorZhiguo ZHENG
Life of this patent
Estimating the term…
Abstract
The present invention relates to an application of 5-bromo-2-(α-hydroxyamyl) sodium benzoate salt (BZP) in treatment of ischemic cardiovascular and cerebral vascular diseases, in particular to a BZP compound for treatment of ischemic stroke and a treatment method, and more specifically, relates to a treatment solution for treating mild and moderate acute ischemic stroke by using the BZP and a pharmaceutical composition comprising the BZP.
Claims25
A method for preventing or treating cardio-cerebral ischemic diseases or improving cardio-cerebral circulation disorders or anti-thrombosis in an individual, the method comprising administering an effective amount of sodium 5-bromo-2-(α-hydroxypentyl)benzoate (BZP) compound, wherein the BZP compound has the following structure:
A method according to any one of the preceding claims, wherein the individual is a human.
The method according to any one of the preceding claims, wherein the individual has a time from stroke onset to drug administration of not more than 24 hours, preferably the individual is a human patient with a time from stroke onset to drug administration of 6-24 hours.
A method according to any one of the preceding claims, wherein the treatment achieves one or more of the following improved effects in the individual:
- (1) Improving the neurological function score and reducing the NIHSS score;
- (2) Improving neurological function outcomes and reducing mRS scores;
- (3) Reducing the volume of cerebral infarction;
- (4) Reducing the recurrence of ischemic stroke;
- (5) Reducing the hemorrhagic transformation of ischemic stroke, including symptomatic intracranial hemorrhage and asymptomatic hemorrhagic transformation;
- and/or
- (6) Reducing the mortality of ischemic stroke.
The method according to any one of the preceding claims, wherein the dosage regimen has a lower incidence of adverse events than other dosage regimens and achieves better improved effects than other dosage regimens.
The method according to any one of the preceding claims, wherein BZP is administered by parenteral route, preferably by intravenous injection or intravenous infusion.
The method according to any one of the preceding claims, wherein BZP is administered in the form of a pharmaceutical composition such as sterile lyophilized powder or an injection reconstituted from sterile lyophilized powder in a pharmaceutically acceptable liquid carrier.
A single pharmaceutical dosage unit, characterized by comprising sodium 5-bromo-2-(α-hydroxypentyl)benzoate (BZP) compound, wherein the single pharmaceutical dosage unit comprises the BZP compound in the dose of 25-400 mg, such as 50-400 mg, preferably 50-300 mg, more preferably 50-250 mg, even more preferably 100-250 mg, for example 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg or 400 mg.
Dependencies are inferred from the claim text.